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Summary 
The heterodimeric ol4 integrins c~4~7 lymphocyte Peyer's patch adhesion molecule ([LPAM]-I) 
and ol431 (very late antigen-4) are cell surface adhesion molecules involved in lymphocyte trafficking 
and lymphocyte-cell and matrix interactions. Known cellular ligands include vascular cell adhe- 
sion molecule (VCAM)-I, which binds to ~431 and ol437, and the mucosal addressin cell adhe- 
sion molecule (MAdCAM)-I, which binds to ol437. Here we show that the o~4 chain of these 
integrins can itself serve as a ligand. The c~4 chain, immunoaffinity purified and immobilized 
on glass slides, binds thymocytes and T lymphocytes. Binding exhibits divalent cation require- 
ments and temperature sensitivity which are characteristic of integrin-mediated interactions, and 
is specifically inhibited by anti-cx4 integrin antibodies, which exert their effect at the cell surface. 
Cells expressing exclusively c~4/~7 (TK-1) or c~431 (L1-2) both bound avidly, whereas ol4-negative 
cells did not.  A  soluble 34-kD ol4 chain fragment retained binding activity, and it inhibited 
lymphocyte adhesion to ~4 ligands. It has been shown that c~4 integrin binding to fibronectin 
involves an leucine-aspartic acid-valine (LDV) motif in the HeplI/IIICS region of fibronectin 
(CS-1 peptide), and homologous sequences are important in binding to VCAM-1 and MAdCAM-1. 
Three conserved LDV motifs occur in the extracellular sequence of c~4. A synthetic LDV-containing 
c~4-derived oligopeptide supports c~4-integrin-dependent lymphocyte adhesion and blocks binding 
to the 34-kD ol4 chain fragment. Our results suggest that r  and r  integrins may be 
able  to bind to the ol4  subunit on adjacent cells,  providing a novel mechanism for ol4 inte- 
grin-mediated and activation-regulated lymphocyte interactions during immune responses. 
T 
he ol4 integrins cr437 (lymphocyte Peyer's patch adhe- 
sion molecule [LPAM]I-1)  and c~4~1 (very late antigen 
[VLA]-4) are adhesion molecules important in lymphocyte 
migration and cell-cell binding. VLA-4 mediates leukocyte 
adhesion to fibronectin (1-3) and the cytokine-inducible en- 
dothelial cell ligand vascular cell adhesion molecule (VCAM)-I 
(4-8). Differentially spliced forms of VCAM-1 with variable 
numbers of Ig domains have been identified in different spe- 
1 Abbreviations used in  this paper: BOG, octylglucoside; Endo F,  en- 
doglycosidase  F; FBS, fetal  bovine serum; HEV, high endothelial  vanules; 
HSA, heat-stable  antigen; ICAM, intracellular  adhesion molecule;  LDV, 
leucine-aspartic acid-valine; LPAM, lymphocyte  Peyer's patch adhesion 
molecule; PP, Peyer's  patch; MAdCAM, mucosal  addressin cell adhesion 
molecule; VCAM, vascular cell adhesion molecule; VLA, very late an- 
tigen. 
cies (9-12).  LPAM-1 has been implicated as a lymphocyte 
homing receptor involved in binding to Peyer's patch (PP) 
high endothelial venules (HEV) in frozen sections (13,  14) 
and in lymphocyte homing to PP and the intestinal lamina 
propria (15). The ligand expressed on the HEV of PP is the 
addressin MAdCAM-1 (16, 17). Only r  cells can 
bind to MAdCAM-1, whereas both o~431 or 0~4/37 cells can 
bind to fibronectin and VCAM-1  (17,  18). 
Despite the fact that lymphocytes do not express any of 
the known ligands for or4 integrins, certain antibodies to cr 
were found to block cell-cell interactions between lymphoid 
subpopulations (19, 20) or to induce homotypic aggregation 
of lymphoid cells, which is blocked by other ol4- or/37/31- 
specific antibodies (21-26).  It has been proposed that such 
aggregation may reflect that lymphocytes express specific coun- 
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Volume 182  May 1995  345-355 terligand(s)  for c~4 integrins or, alternatively, that or4 inte- 
grins  are capable of interacting in  a homotypic fashion. 
Here we report that the isolated oe4 integrin chain itself, 
as well as leucine-aspartic acid-valine (LDV)-containing pep- 
tides of oe4, can serve as ligands for recognition and binding 
by lymphocytes oe4B1 and oe4f17. Our results suggest a novel 
c~4-c~4 binding mechanism that could participate in diverse 
o~4-dependent cell-cell interactions. 
Materials and Methods 
Cell Culture.  The murine bend3  endothelioma cell line was 
kindly provided by Dr. W. Risau (Bad Nauheim, FRG) and was 
maintained in DMEM with high glucose (Life Technologies,  Eg- 
genstein, FRG) containing 10% low endotoxin fetal bovine serum 
(FBS)  (Life Technologies). Cells  were activated with LPS from 
Salmonella enteritidis  (Sigma, Deisenhofen, FRG) at a dose of 1 #g/ml 
for 4 h at 37~  The T  cell lymphoma line TK-1 (13, 27), the 
lymphoma cell lines ESb 289 and Eb (28), and the B lymphoma 
line L1-2 were maintained in RPMI 1640 medium supplemented 
with 10% FBS, 2 mM L-glutamine,  10 mM Hepes, and 50 mM 
2-ME (culture medium). The T  cell hybridoma cell line BI 141 
(29) was kindly provided by A. Reske-Kunz (University of Mainz, 
Mainz, FRG) and was maintained in Iscove's medium supplemented 
with 5% FBS, sodium pyruvate, and 50 mM 2-ME. All cells were 
kept at 37~  5% CO2, and 100% humidity. Spleen and thymus 
cells were collected from 6-8-wk-old DBA/2 mice. Erythrocytes 
were  lysed  by brief incubation  in  155  mM  NH4C1,  0.1  mM 
EDTA,  10 mM KHCO5 solution. T  lymphocytes were purified 
from spleen by passage over nylon wool followed by treatment with 
B220 mAb RA32C2 (30) and rabbit complement (Camon, Wies- 
baden, FRG). T lymphoblasts were induced from splenic lympho- 
cytes  by activation with  5  /zg/ml Con  A  in  RPMI  1640 sup- 
plemented with 10% FBS and 50 mM 2-ME for 48 h. Blast cells 
were purified by Percoll centrifugation (Pharmacia,  Freiburg, FRG) 
and cell clumps were dissociated by treatment with PBS containing 
5 mM EDTA. 
Antibodies.  The mAb 5/3 was obtained by immunizing rats 
with bend3 cells stimulated for 4 h with LPS. Animals were in- 
jected subcutaneously with live cells (1-2  x  107 per injection) in 
PBS and four booster injections were given with 2-wk intervals. 
Spleen cells from these rats were fused with Sp2/0 cells as described 
(31) and hybridomas that were able to block the binding of thymo- 
cytes to LPS-activated bend3 cells were selected, mAb 5/3 (IgG2b) 
was obtained from the parental blocking subclone 228/10 by lim- 
iting dilution cloning, mAb 7/1 (IgM) was obtained from the same 
subclone and has no blocking potential. It recognizes a cell surface 
molecule with unknown function and was used for control pur- 
poses. Other mAbs were: PS/2 (32) and R1-2 (13) directed against 
c~4 integrins, FD441 (TIB 213) and FD 18.5 (33) recognizing the 
c~ chain of LFA-1, 30G12 against mouse CD45,  MK2.7 against 
VCAM-1 (34), YN.1/1.7 against intracellular adhesion molecule-1 
(ICAM-1) (35), 12-15 against mouse CD2 (36), DATK-32 against 
a combinational epitope of oe437 (17), -Fib 30 against 37 (15), 324 
against the L1 adhesion molecule (37), and 79 against  HSA (38). 
Peptides.  Peptides  were synthesized using Fmoc strategy and 
purified by preparative HPLC. They were characterized further by 
analytical HPLC and mass spectroscopy. Peptides were synthesized 
with an NH2-terminal Cys residue.  The following peptides were 
used: CS-1, CEILDVPST; LDV-oe4(1), CNVSLDVHRKA; LDV- 
c~4(2), CSFLLDVSSLS:  LDV-o~4(3), and CFNVLDVQTTT. For 
control, the peptide VAIYDDMESLPLTGT was  used. Peptide- 
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carrier protein conjugates for cell adhesion were produced by cross- 
linking N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP)-acti- 
vated rabbit IgG with peptides (39, 40). The following peptides 
were conjugated: CS-1, CDELPQLVTLPHPNLHGPEILDVPST; 
LDV-o~4(1), CVLFYNVSLDVHRKAESPSRF;  CMFSTKSAW- 
LRNGGADQGPRG (cr  signal peptide) was used for control pur- 
pose. Peptide-carrier conjugates were coated to glass slides as de- 
scribed below. 
Cytofluorography.  The staining of cells with hybridoma super- 
natant- and PE-conjugated goat antibodies to rat immunoglobulins 
(SERVA, Heidelberg, FRG) has been described in detail elsewhere 
(41). Stained cells were analyzed with a FACScan  |  fluorescence- 
activated  cell analyzer (Becton Dickinson, Heidelberg, FRG). 
A~nity Purification of Cell Su[face Antigei~s.  mAbs were cou- 
pled to CNBr-activated Sepharose  (Pharmacia)  and used for the 
purification of antigen by affinity chromatography as previously 
described (42). Briefly, cells (ESb lymphoma, TK-1 cells, or pooled 
thymocytes and splenic lymphocytes) were lysed in 20 mM Tris/HC1, 
pH 8.0, containing 2% NP-40, 150 mM NaC1, 1 mM PMSF (lysis 
buffer). Lysates were cleared by centrifugation and passed over a 
normal rat IgG-Sepharose column followed by the specific anti- 
body column. The column was washed with lysis buffer followed 
by buffer I (20 mM Tris/HC1, pH 8.0, 500 mM NaC1, 0.2% NP 
40) and buffer II (20 mM Tris/HC1, pH 8.0, 0.05% NP-40). Sub- 
sequently, the column was washed with buffer III (50 mM Tris/HC1, 
pH 8.0, 150 mM NaC1, 50 mM 3-octylglucoside [BOG]) and then 
eluted with 100 mM diethylamine/HC1, pH 11.5, 150 mM NaC1 
containing 50 mM BOG. Peak fractions of the eluate were neutral- 
ized and analyzed by SDS-PAGE after labeling with 12si using Io- 
dobeads  (Pierce, Oud-Beijerlandt, The Netherlands) or by silver 
staining.  VCAM-1 and ICAM-1 were isolated by affinity chroma- 
tography from lysates of spleen, liver, and kidney of animals treated 
with TNF-o~ for 16 h. 
Cell-binding Assay.  Isolated antigen in BOG was diluted 1:10 
to 1:30 with 10 mM Tris/HC1, pH 8.0, 150 mM NaC1 and coated 
to Labtek glass chamber slides (Nunc, Wiesbaden, FRG) for 16 h 
at 4~  Fibronectin (Sigma) in PBS was coated at a concentration 
of 10 #g/ml for 16 h at 4~  Wells were blocked with 2% BSA 
in PBS or 1% OVA in TBS for 2 h at room temperature, washed 
with HBSS containing 10 mM Hepes, 2 mM Ca  2+, and 2 mM 
Mg  ~§  (binding buffer), and used for the assay. For binding, cells 
(5-10 x 106/ml) were suspended in the same buffer and 0.2-ml ali- 
quots were added to the coated slides. The binding assay was per- 
formed for 30 min at room temperature without shaking and the 
slides were fixed in 2% glutaraldehyde/PBS after briefly dipping 
into PBS. For antibody- or peptide-blocking studies, cells were prein- 
cubated with purified antibody (40 #g/ml final concentration or 
as otherwise indicated)  or peptides (150/zg/ml or otherwise indi- 
cated) for 10 min at room temperature and then transferred to the 
chamber slides. In some experiments, cells and coated slides were 
incubated separately with antibody and then washed before the ex- 
periment. Cation dependence was determined by preincubation of 
cells with 5 mM EDTA or 5 mM EGTA in HBSS with 10 mM 
Hepes for 10 rain and then used for the assay. For Mn  2§  activa- 
tion, the Ca  2§ and Mg  2+ ions in the buffer were substituted with 
0.5 mM Mn 2§  For PMA activation, the cells were incubated in 
50 ng/ml PMA for 10 rain before the assay. Cell binding was mea- 
sured by counting six independent fields at a magnification of 10 
by video microscopy using IMAGE 1.47 software. 
Biochemical Analysis.  Lactoperoxidase-catalyzed  iodination of 
surface glycoproteins on intact cells, cell lysis in the presence  of 
NP-40, immunoprecipitation using protein G-Sepharose or pro- 
tein A/MAR, treatment of precipitates with endoglycosidase F/N- 
glycosidase F (Boehringer Mannheim, Mannheim, FRG) has been 
Homophilic Binding of a4 Integrins described elsewhere (41). SDS-PAGE was performed on 10% slab 
gels. Peptide mapping was carried out as described (43). Briefly, 
iodinated 80-, 70-, and 34-kD fragments, respectively, were elec- 
trophoretically separated, eluted from the gel, and digested with 
papain (2/~g/ml) in 125 mM Tris/HC1, pH 6.8, containing 0.5% 
SDS, 10% glycerol, and 0.0001% bromphenol blue for 2 h. Diges- 
tion was stopped by boiling, and 2-ME and SDS were added to 
a final concentration of 10% and 2%, respectively. The samples 
were separated on a 15% SDS-PAGE. Gels were dried and exposed 
to x-ray-sensitive films (Kodak X-Omat;  Siemens, Mannheim, 
FRG). 
R.esults 
mAb 5/3 is Specific  for the or4 Subunit.  mAb 5/3 was pro- 
duced by immunizing rats with activated bend3 endothelioma 
cells. The antibody was initially selected because of its ability 
to  block  the binding  of thymocytes to  the  activated en- 
dothelioma cells,  mAb 5/3  stained the endothelioma cells 
and also reacted with lymphocytes in FACS  |  analysis (Becton 
Dickinson). Functional studies showed that the antibody not 
only blocked the binding of lymphocytes to endothelioma 
cells but also to fibronectin. This observation suggested that 
it might react with ct4 integrins. Biochemical analyses with 
the antibody were carried out using 125I surface-labeled ESb 
lymphoma cells. These cells express c~4 and an unknown/3 
chain. Fig.  1 A  (lane I ) shows that mAb 5/3 precipitated 
a major band of "~150 kD and two additional bands of 80 
and 70 kD. The 150-kD band represents the intact a4 chain 
and the smaller bands are proteolytic cleavage fragments of 
the a4 chain that exist in the membrane (44, 45). A/3 chain 
is not visible under the solubilisation conditions since in the 
mouse, the cx4/3 heterodimers are not stable in the absence 
of Ca  2+ and Mg  z+ ions (13, 46).  Treatment of the precipi- 
tate with endoglycosidase F (Endo F) to remove N-linked 
glycans decreased the apparent mass of the bands to 92, 60, 
and 50 kD,  respectively (lane 2). The 7/1 control antigen 
was reduced from "~50 to 34 kD after Endo F treatment (lanes 
3 and 4).  Additional experiments indicated that mAb 5/3 
and the established cx4-specific mAb PS/2 precipitated iden- 
tical protein bands from ESb ceils (lanes 5 and 6). Both mAbs 
were also compared for their ability to precipitate o~4 inte- 
grins from TK-1 cells (tx4/37) that were solubilized in the 
presence of Ca  2+ and Mg  2+ ions.  Under these conditions, 
both mAbs showed the expected ix4 chains plus the/37 chain 
(lanes 8 and 9) that migrated at "~130 kD under nonreducing 
conditions. 
Fig. 1 B shows that mAb 5/3 stained TK-1 cells (c~4/37) 
and L1-2 cells (tx4/31) similar to mAb PS/2.  In contrast to 
PS/2, which cross-reacts with human o~4 integrins, the mAb 
5/3 did not stain human PBLs, suggesting that the two anti- 
bodies reacted with different epitopes on the cx4 chain. 
To localize the mAb 5/3 epitope on the ix4 subunit, the 
tx4/37 heterodimer was isolated from iodinated TK-1 cells using 
mAb PS/2 bound to protein G. After washing, the bound 
antigen was eluted at pH  11.5, neutralized, and reprecipi- 
tated using mAb 5/3-Sepharose or control-Sepharose. Fig. 
1 D shows that in the absence of divalent cations the hetero- 
dimer dissociated since the mAb 5/3 only reprecipitated the 
150-kD t~4 chain and the 80-kD subffagment (lane 3). The 
control Sepharose did not precipitate any component of the 
0t4/37 heterodimer (lane 2). These results suggested that the 
mAb 5/3 epitope was located on the NH2-terminal 80-kD 
portion of the ix4 subunit. 
The Purified or4 Sub'unit Binds Lymphocytes.  We investigated 
whether the isolated ct4 subunit could bind cells.  The an- 
tigen was isolated on a mAb 5/3-Sepharose column initially 
from ESb lymphoma lysate and the washing steps were car- 
ried out in the absence of Ca  2+ and Mg  z+ ions to favor loss 
of the 13 chain. Bound material was eluted at pH 11.5 and 
the individual fractions were tested in ELISA. Antigen con- 
taining fractions were strongly reactive with mAb PS/2 to 
the ix4 subunit (not shown). When the peak fraction was 
iodinated and reanalyzed by SDS-PAGE,  the expected bands 
of 150, 80, and 70 kD were seen for the or4 subunit (see Fig. 
1 C, lane 1 ). In addition, minor bands at ~60, 46, and 34 
kD, respectively, were observed. These bands were not de- 
tectable in the control antigen (7/1) obtained from the same 
lysate (Fig.  1, C, lane 2),  suggesting that they represented 
most likely degradation products generated during the elu- 
tion procedure (see also discussion of the 34-kD band below). 
The affinity-purified c~4 subunit was coated to glass slides 
in increasing amounts and residual binding sites were blocked. 
As shown in Fig.  2 A, thymocytes adhered to the immobi- 
lized c~4 subunit in a concentration-dependent fashion. No 
binding was seen to the control antigens 7/1 (Fig.  2 A) or 
HSA (see Fig. 2 B) isolated from the same lysate.  As illus- 
trated in Fig. 2 B, high levels of binding were observed with 
resting T  lymphocytes or Con A-activated T  cell blasts. 
To rule out the possibility that small amounts of B chain 
were copurified under the isolation conditions, the ct4 subunit 
was also isolated from the tx4/37-positive TK-1 cells since an- 
tibodies to the B7 chain are available. The 5/3 column-eluted 
material could also promote cell binding and revealed in ELISA 
a strong reactivity with mAb PS/2 but not with the/37- 
specific mAb Fib 30 (15) or with mAb DATK32, respectively, 
recognizing a combinational epitope of the ix4 and 137 subunit 
(17; data not shown). 
Integrins Are Involved in the Binding to the or4 Subunit.  Fig. 
3 shows that the binding of thymocytes to the or4 subunit 
was cation dependent since pretreatment of the cells with 
EDTA or EGTA abolished binding. It was fully restored when 
Ca  2+ and Mg  2+ ions were added back to the assay (data not 
shown).  Incubation  at  4~  also  inhibited  adhesion.  The 
binding of cells was enhanced by pretreatment with PMA 
and Mn  2+. The adhesion of thymocytes to fibronectin (Fig. 
3) paralleled the binding to the or4 subunit and was equally 
affected. 
The divalent cation requirement and temperature depen- 
dency suggested that the binding to the ix4 subunit might 
involve integrins. To further support this conclusion, we tested 
ol4-positive or c~4-negative cells for their ability to bind. The 
T  cell hybridoma BI 141  and the T  lymphoma Eb do not 
express or4 integrins, as shown by FACS  |  staining with mAbs 
PS/2 or 5/3, respectively. We compared the binding of these 
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in Fig.  4,  both TK-1 and L1-2 cells adhered well to the c~4 
subunit,  the  binding  being  further  increased  after  PMA 
pretreatment.  In contrast,  BI 141  and Eb cells showed low 
level binding  that was slightly enhanced  after pretreatment 
of the  cells  with  PMA  but  remained  low  (Fig.  4). 
Human PBL bound weakly to the c~4 subunit. The binding 
was, however, strongly enhanced after PMA treatment of the 
cells  (Fig.  4). 
Inhibition of  Binding in the Presence of cr4-specific  Antibodies. 
Fig.  5  A  shows  that  antibodies  to  LFA-1  or  to  CD45  did 
not  effect the  celt binding  to the  or4  subunit.  In contrast, 
antibodies PS/2 and R1-2 directed against o~4 integrins were 
potent inhibitors, Similar blocking with ot4-specific antibodies 
was observed when resting T  lymphocytes or TK-1 cells in- 
stead  of thymocytes  were  studied  (data  not  shown). 
mAb 5/3  also blocked the binding  of thymocytes to the 
purified ol4 subunit  in a dose-dependent  manner (Fig. 5 B). 
To determine whether the blocking effect occurred at the im- 
mobilized or4 subunit  or at the cell surface, the coated glass 
slide and  the cells were  preincubated  separately with  mAb 
5/3 and then washed to remove the antibody.  As shown in 
Fig.  5/3,  preincubation  of cells with mAb 5/3 blocked cell 
binding  to the cr  subunit.  Also the binding  to fibronectin 
was fully blocked (not shown). Preincubation of the c~ subunit 
coated  to the  glass  slide  did not  affect the binding  of cells 
(Fig.  5 B).  This suggested that in order  to block,  the anti- 
body had  to first bind  to  the lymphocyte cell surface.  The 
data also indicated that two distinct epitopes on the c~4 chain 
existed:  a binding epitope that can be blocked by mAb 5/3 
and an attachment epitope(s) that is not blocked by this an- 
tibody. 
The binding of human PBLs to the o~4 subunit was blocked 
in the presence of mAb PS/2 (which cross-reacts with human 
cells) but  not mAb 5/3  (data not shown).  This is in agree- 
ment  with  the  observation  that  mAb  5/3  does  not  cross- 
react  with  human  cells  (Fig.  1 B). 
Figure  1.  mAb 5/3 is a novel or4 subunit-specific antibody. (A) ESb 
lymphoma cells were labeled with 125I and lysed in the absence of Ca  z+ 
and Mg  2  + ions. After incubation with primary mAbs, the immunocom- 
plexes were precipitated using  Sepharose-bound protein  G  or protein 
A/MAR (for mAb 7/1). Half  of the precipitated material was treated with 
Endo F to remove N-linked glycans. TK-1 lymphoma cells were labeled 
with 1251 and lysed in the presence of Ca  2+  and Mg  2+ ions to preserve 
the ~4~7 heterodimer. After incubation  with primary mAbs, the im- 
munocomplexes were harvested using Sepharose-protein G. Samples  were 
analyzed by SDS-PAGE. Lanes 1, ESb, mAb 5/3; lane 2, ESb, mAb 5/3 
Endo F treated; lane 3, ESb, mAb 7/1 Endo F treated; lane 4, ESb, mAb 
7/1; lane 5, ESb, mAb 5/3; lane 6, ESb, mAb PS/2; lane 7, ESb, negative 
control protein G only; lane 8, TK-1, mab 5/3; lane 9, TK-1, PS/2. Note 
that  samples in lanes 8 and 9 were run under  nonreducing conditions. 
(B) Indirect immunofluorescence  staining with mAb 5/3 and the c~4 inte- 
grin mAb PS/2. Cells (TK-1, L1-2, human peripheral blood leukocytes) 
were stained by indirect immunofluorescence  using mAb 5/3 or PS/2 fol- 
lowed by PE-conjugated goat antl-rat IgG. For negative control, the first 
antibody was omitted. (C) Analysis of a~nity-purified 0~4 chain. The 4or 
subunit was isolated  from ESb cells by affanity  purification on 5/3-Sepharose 
in the absence of Ca  2+ and Mg  z+ ions and eluted with 50 mM diethyl- 
amine/HC1, pH 11.5, 150 mM NaC1 containing 50 mM BOG. An ali- 
quot of the sample was iodinated and reanalyzed (lane I ). For control, 
the 7/1 antigen isolated from the same lysate is shown (lane 2). Note that 
the 34-kD fragment (see text) is visible only after longer exposure of the 
gel and is not seen here. (/9) Epitope localization for mAb 5/3. TK-1 lym- 
phoma cells were labeled with 12si and lysed in the presence of Ca  2  + and 
Mg  2+ ions to preserve the cr  heterodimer. After incubation with mAb 
PS/2 adsorbed to Sepharose-protein G the complex was eluted with 100 
mM diethylamine/HC1, pH 11.5, 150 mM NaC1 containing 50 mM BOG, 
neutralized and reprecipitated  by the addition ofmAb 5/3-Sepharose. Lane 
1, TK-1, mAb PS/2 (input); lane 2, reprecipitated 7/1-Sepharose; lane 3, 
reprecipitated 5/3-Sepharose. The positions of molecular mass marker pro- 
teins (14C rainbow markers; Amersham) designated in kilodaltons are 
shown on the left margins. 
348  Homophilic Binding of c~4 Integrins Figure 2.  Binding of lymphocytes to the ~x4 subunit. The integrin cx4 chain or control antigen in BOG were coated to glass slides and were blocked 
with 1% OVA. Cells in HBSS/10 mM Hepes containing Ca  2+ and Mg  2+ were tested for binding. (A) Dose-response curve for the binding of thymo- 
cytes to the cz4 subunit or to 7/1 Ag (control antigen). (13) Binding of splenic T lymphocytes  binding to HSA (a) or to the ~x4 subunit (b). Binding 
of Con A-activated splenic T cells to HSA (c) or to the cx4 subunit (d). 
Characterization of  an or4 Chain Fragment.  Upon prolonged 
storage, we noticed that the isolated c~4 subunit was degraded, 
yet could still mediate cell binding when coated to glass slides. 
When bound and reeluted from the mAb 5/3 column, the 
material retained the ability to bind cells. We therefore purified  1|~ 
the active fragment by Mono Q  ion exchange chromatog-  1000 
raphy.  Individual  fractions were  analyzed for cell binding 
ability. As shown in Fig. 6, the binding activity eluted with  ~ 
the major protein peak from the column.  When  iodinated  m" 
and  analyzed by SDS-PAGE,  a  prominent  band  migrating  ~  i 
at "~34 kD under reducing conditions was detected (Fig.  7  ~001 
A, lane I ). Treatment with Endo F  showed that the 34-kD  0 
protein fragment was resistant  (lanes 4 and 5), whereas the 
7/1 control antigen (lanes 2 and 3) was cleaved under these  ,~o- 
8000 
[]  Fibronectln 
￿9  c~4 subunit 
6000" 
Ir 
J~  4000'  w 
2000' 
O 
cold  Ca,Mg  EDTA  EGTA  Mn  PMA 
binding conditlons 
Figure 3.  Requirements  for the binding of  thymocytes  to the cz4 subunit. 
Temperature and ion requirements for the binding of thymocytes to the 
or4 subunit or fibronectin. 
8OO 
E 
e- 
￿9  .!  4OO 
0 
..1= 
.~  2OO 
0 
8O0 
600 
400 
200 
0 
￿9  BI141 
[]  B1141.(.PMA 
I 
HSA  ~4 lubunh 
￿9  LI-2 
Llo2+PMA 
HSA  rL4 eubunit 
￿9  human PBL 
[]  humanPBL+PMA 
HSA  a4subunN 
￿9  Eb 
1~  Eb+PMA 
i 
HSA  a4 subunlt 
HSA  a4 subunlt 
Differential binding to the cz4 subunit by ol4-positive  and  Figure 4. 
-negative cells. Binding of BI 141 (cx4 negative), Eb cells (cx4 negative), 
TK-1 cells  (r  or L1-2  cells (c~431)  and human PBL to the cx4 subunit 
or to HSA. Cells  were  also pretreated  with PMA for 15 min before  the assay. 
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Figure  5.  Antibodyinhibitionofthymocytebindingtothec~4subunit. 
(.4) Inhibition of thymocyte binding to the oe4 chain by antibodies  to ol4 
integrins (R1-2 and PS/2) but not by LFA-1 antibodies (FD441 and FD18.5) 
or a CD45 control antibody.  (B) Blocking of mAb 5/3 requires binding 
to ceils. Either thymocytes or the ol4 subunit-coated  glass slide were prein- 
cubated with mAb 5/3 for 15 min, washed twice, and used in the binding 
assay. 
conditions. The 34-kD protein migrated at '~25 kD under 
nonreducing conditions that implicated the presence of in- 
trachain disulfide bridges (not shown). It could be reprecipi- 
tated as expected  with mAb 5/3-Sepharose (Fig. 7 B, lane 
3) but not by control antibodies coupled to Sepharose (lanes 
2, 4, and 5),  suggesting that it was a fragment of the cz4 
subunit. 
The NH2 terminus of the 34-kD fragment was blocked. 
To determine the location within the oL4 subunit, peptide 
mapping analyses were carried out (Fig. 7 C). The iodinated 
80- and 70-kD fragments of the cz4 subunit and the 34-kD 
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Figure  6.  Isolation of a 34-kD fragment derived from the r  subunit. 
Ion exchange chromatography on a Mono Q column. Degraded cx4 subunit 
was dialyzed against buffer A, bound to the column, and eluted with a 
linear gradient of buffer B. An aliquot  of each fraction was diluted 1:20 
in 10 mM Tris/HCl, pH 8.0, 150 mM NaC1 and coated to Labtek glass 
chamber  slides for  16 h  at 4~  The binding of thymocytes  was tested 
as outlined in Materials and Methods. 
fragment were excised from the gel and digested with papain. 
Gel analysis of the digested material  showed shared bands 
in the 80- and 34-kD  fragments,  respectively,  which were 
absent in the 70-kD fragment (Fig. 7 C). These results sug- 
gested that the 34-kD fragment was derived from the 80-kD 
portion of the cz4 molecule. This assignment is consistent 
with the localization of the mAb 5/3 epitope on the 80-kD 
subfragment  (see Fig.  1 D). 
When the ceU-binding ability of the intact oe4 subunit and 
the 34-kD fragment were compared, no differences were ob- 
served. Also, the binding to the fragment was blocked by 
cz4-specific antibodies and it required the presence of c~4 inte- 
grins on the cell surface. Thus, the 34-kD fragment had re- 
tained the mAb 5/3 epitope and the attachment  epitope in- 
volved  in cell binding. 
The Fragment Blocks ol4 Integrin-dependent Cell Binding. 
The 34-kD  fragment  was soluble in PBS and was studied 
for its potential to block ot4-dependent  cell binding. In the 
presence of 2 #g/ml of the fragment the binding of thymo- 
cytes to fibronectin was inhibited by 60  _+ 3%, the binding 
to purified VCAM-1 by 43  _+  5%  (mean of three experi- 
350  Homophilic Binding of oe4 Integrins ments). Binding of thymocytes  to the or4 fragment itself  was 
blocked  by  >90%  under  these  conditions,  whereas  the 
binding to purified ICAM-1, which is LFA-1 mediated, was 
not affected. 
The cr4-subunit Contains LDV Peptide Motifs.  The ability 
of the fragment to partially block the binding to VCAM-1 
and fibronectin prompted us to search for structural similari- 
ties between the oe4 subunit and its ligands. The LDV pep- 
tide sequence  within the CS-1  peptide of fibronectin was 
shown to be the minimal sequence to promote oe4~/1-mediated 
cell binding (39,  47).  Related sequences  like IDS or LDT 
appear  to  be  important  in  the  binding  to  VCAM-1  or 
MAdCAM-1, respectively (48-51;  Briskin, M. J., and E. C. 
Butcher, manuscript  submitted for publication). We used these 
amino acid motifs to screen the mouse oe4 sequence. As shown 
in Table 1, the ol4 subunit contains three LDV motifs that 
are conserved in the human oe4 sequence.  The LDV-oe(1) is 
likely to be shared between the intact subunit and the 34-kD 
fragment. 
Peptide-mediated  Inhibition of  Cell Binding.  To test whether 
the LDV sites were important in the cell binding to the oe4 
subunit, peptides covering all three LDV sites were synthe- 
sized  and used for inhibition studies.  Fig. 8 A  shows that 
at 150 #g/ml, the LDV-c~4(1) peptide was the only peptide 
that could efficiently inhibit the binding of thymocytes to 
the 34-kD fragment. The CS-1 peptide from fibronectin could 
also block the cell adhesion; however,  it required approxi- 
mately fivefold higher concentration. Similar results were ob- 
served when the intact or4 subunit was used as substrate (data 
not shown). A mixture of the LDV-ce4 peptides could par- 
tially block the adhesion of thymocytes to fibronectin (Fig. 
8 B). The binding to fibronectin was also inhibited by CS-1 
peptide, as well as by mAb 5/3.  The degree of inhibition 
seen with both reagents suggested that VLA-5, beside oe4 
Figure  7.  Biochemical  characterization  of the oe4 Subunit Fragment. 
(A) Lane  I, an aliquot  of the peak fraction  eluted from the Mono Q was 
iodinated  and analyzed.  The iodinated  34-kD fragment  or the control  an- 
tigen 7/1 was treated  for 1 h with Endo-F and analyzed  by SDS-PAGE. 
Lane 2, 7/1 antigen; lane  3, 7/1 antigen  plus Endo  F; lane  4, 34-kD c~4 
fragment; lane  5, 34-kD ce4 fragment  'plus Endo F. (B) Reprecipitation 
of the iodinated  fragment:  lane 1, 34-kD fragment  input; lane  2, mAb 
7/1 Sepharose; lane  3, mAb 5/3 Sepharose; lane  4, mAb 12-15 (CD2)- 
Sepharose; lane  5, mAb 324 (L1)-Sepharose.  (C) Aflhnity-isolated  oe4 subunit 
was iodinated  and separated  by SDS-PAGE  (lane  1  ). The c~4 subunit  (150- 
kD), 80-kD, 70-kD, and 34-kD fragments,  respectively,  are indicated  by 
arrowheads. The bands were  excised  from  the gel and subjected  to peptide 
mapping. Lane  2, 34-kD fragment,  papain digested;  lane  3, 70-kD frag- 
ment, papain digested; lane 4, 80-kD fragment, papain digested. Small 
arrowheads  at the right  margin  of  lanes  2 and 4 denote  identically  migrating 
proteolytic fragments. 
Table  1.  Amino Acid Motifs of oe4 Integrin Ligands Involved 
in Cell Binding 
Species  Protein  Sequence 
FN CS1 
FN CS1 
FN CS1 
FN H1 
PEI  LDVPST 
PDML  DVPSV 
PEI  LDVPTD 
TTAVDSPSN 
Hu/Ra/Bo 
Ch 
Xe 
Hu/RaJBo/Ch 
Hu/Ra 
Mu 
Hu 
Mu/Ra 
Mu 
Mu 
Hu 
VCAM-1 D1 
VCAM-1 D1 
VCAM-1 D4 
VCAM-1 D4 
MAdCAM-1 D1 
~(1) 
(2) 
o~ (3) 
ct4 (1) 
(2) 
(3) 
RT  QI  DS  P  L  NG 
RTQI  DS  P  L  NA 
RTCI  DSrPLSG 
RTCI  DS  P  L  NG 
WRG  L  DTS  L  GS 
N V S~H  R K A 
S  F  L  ~'~"'".~,,~SS  L  S 
F  N V  ~I~QT  T  Z 
N  M s  R  K  A 
~!~  ~  S~~4  S  L S  S  F  L  ~,~ 
F  NI  ~QTT'I" 
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subunit. (A) Inhibition of  thymocyte  binding to the 34-kD fragment using 
peptides. Cells were preincubated with peptides at 150 #g/ml (CS-1 pep- 
tide at 700/zg/ml) for 10 min and then tested for binding to the 34-kD 
o~4 fragment. (B) Inhibition of thymocyte-binding  to fibronectin using 
peptides at the same concentration as in A. (C) Binding of cells to pep- 
tide-IgG conjugates. CS-1 peptide, the LDV-ol4(1)  peptide, and a negative 
control peptide were coupled to rabbit IgG, coated to glass slides, and 
tested for the binding of thymocytes  as described  in Materials and Methods. 
integrins  an additional fibronectin receptors on thymocytes 
(52) is either  not  active or present  in too low amounts  to 
contribute  to  the binding. 
The LDV-ot4 Peptide  Promotes Cell Binding.  To demonstrate 
binding of cells to the LDV-oz4(1) site, the peptide CVLFYN- 
VSLDVHRKAESPSKF was conjugated to rabbit IgG as car- 
rier and was analyzed for its cell-binding capacity. As shown 
in Fig. 8 C,  the LDV-c~4 peptide was as potent as the CS-1 
peptide in promoting cell adhesion.  A control peptide-IgG 
or rabbit  IgG  alone  had  only little  or no effect. 
Discussion 
The ol4 integrin ligands comprise a diverse group of mol- 
ecules with  different structure  and location.  VCAM-1  and 
MAdCAM-1 belong to the Ig superfamily, whereas fibronectin 
is a plasma and extracellular matrix component. Invasin,  an- 
other o~4 integrin-binding protein, is an outer membrane pro- 
tein of Yersinia pseudotuberculosis that  uses/31  integrins,  in- 
cluding VLA-4 on human T  cells as a receptor to enter the 
cell (53, 54). In this report, we demonstrate that the c~4 subunit 
itself can be a ligand for or4 integrin-dependent  lymphocyte 
binding. 
Our studies were initiated by a novel mAb against 0~4 inte- 
grins,  which was obtained by immunizing  with the brain- 
derived endothelioma bend3.  The identification of such an 
antibody was not surprising since bend3 cells could be stained 
with mAb PS/2 and o~4 integrins  can be detected on brain 
endothelial cells in vivo (Engelhardt,  B., and E. C. Butcher, 
unpublished data). Studies using the novel mAb 5/3 in com- 
parison to the established mAb PS/2 indicated that both an- 
tibodies recognized  the  o~4 chain  and  that  the epitope for 
mAb 5/3 was located on the NH2-terminal 80-kD fragment 
of the  oe4 subunit. 
To investigate the functional ability of the c~4 subunit, we 
used the mAb 5/3 for affinity purification of the antigen from 
cell lysates.  Surprisingly,  when immobilized to glass  slides, 
the purified o~4 subunit could avidly bind thymocytes or var- 
ious lymphoid cell populations, whereas control antigens iso- 
lated from the same lysate could not. The cell adhesion was 
temperature  dependent,  required  divalent cations,  and was 
enhanced by PMA or Mn  2+ ions,  suggesting that  integrins 
were involved. Antibody-blocking studies demonstrated that 
mAbs to or4 integrins but no other antibodies were capable 
of inhibiting  the binding  to  the ol4  subunit.  Both ot4/$7- 
and c~4fll-positive mouse cells but also human peripheral blood 
lymphocytes could bind to the c~4 chain, whereas ol4-negative 
cells  could not.  Binding  was also seen to a 34-kD  soluble 
fragment derived from the c~4 subunit. Biochemical data in- 
dicated that  it was derived from the 80-kD portion of the 
ol4 subunit.  The requirements  for the binding  to the frag- 
ment were similar to the intact ol4 chain.  This observation 
ruled out the possibility that the cell binding was mediated 
by residual intact  o~3 heterodimers  in the oL4 preparations. 
Based on the amount of protein,  the fragment was as active 
as the intact  o~4 subunit,  indicating  that  it  had retained  a 
cell attachment  site(s)  that  was present  in the c~4 subunit. 
The fragment  could block o~4 integrin-dependent  binding 
of thymocytes to VCAM-1 and fibronectin but did not im- 
pair the binding of thymocytes to ICAM-1, which is LFA-1 
dependent. The cross-blocking results suggested the involve- 
ment of a structurally related epitope in the binding of c~4 
integrins  to  its ligands. 
Binding of c~431 integrins to fibronectin involves the fibro- 
nectin CS-1 peptide, located in the alternatively spliced type 
III connecting segment (1-3, 39, 47). The LDV amino acid 
motif is the minimal sequence that promotes oL4-dependent 
cell binding (39, 55). As shown in Table 1, homologous se- 
quences to LDV are present in mouse and human VCAM-1. 
Mutation  analysis  of VCAM-1  in  this position  has  shown 
that a D-A exchange introduced into the IDS sequence abol- 
ished the binding  of o~4 integrins  (48).  Other  studies have 
352  Homophilic  Binding of ol4 Integrins shown that residues within a conserved amino acid motif in 
domains 1 and 4 (included the IDS) are required for binding 
to  VLA-4  (49,  50).  CS-1  peptide  also  blocks  the ot4/31- 
mediated binding of cells to VCAM-1 (51). The first domain 
of MAdCAM-1 contains the related LDT motif. Recently, 
a point mutation within MAdCAM-1 has been identified, 
which results in an L-R amino acid exchange in position 61 of 
the protein (Briskin, M. J., and E. C. Butcher, manuscript 
submitted for publication). This alters the motif from LDT 
to RDT in the mutant. When expressed in Chinese hamster 
ovary cells, the mutant MAdCAM-1 protein could no longer 
bind cells in a ot4-dependent manner unless the cells were 
activated with PMA or Mn  2+  ions.  Interestingly, grafting 
of the CS-1 peptide sequence onto a non-or4 integrin-binding 
protein can restore ot4-mediated binding (56), suggesting that 
the LDV epitope can act independently of its environment. 
We analyzed the or4 subunit for similar binding motifs. The 
sequence analysis of the mouse or4 subunit revealed three LDV 
sites that are also present in the human or4 subunit but are 
not  found,  for example,  in  the or6  sequence.  To  analyze 
whether these sites were relevant for the binding, we initi- 
ated peptide inhibition studies. Based on these results, the 
LDV-ot(1) site appeared to be functionally most active.  At 
higher concentrations (>500 gg/ml), the CS-1 peptide was 
also able to block the binding to the e~4 subunit in a specific 
fashion, supporting the notion that the LDV motif could 
indeed be important. Moreover, the LDV-ot(1) site, when cou- 
pled to IgG carrier protein, was as potent as the fibronectin 
CS-1 peptide in promoting cell binding. Thus, the c~4 inte- 
grin chain contains a potent cell-binding motif with the poten- 
tial to support adhesion oflymphocytes through cell surface 
or4 integrins. It is presently unknown whether this ability 
is also preserved in the intact or4 integrin heterodimer. Al- 
though our studies do not address the potential importance 
of conformational alterations that might be induced during 
isolation and coating, it should be pointed out that little is 
known about the range of states  assumed by or4 integrins 
expressed on the cell surface; the existence of free c~ chains 
has been suggested based on studies of cell lines expressing 
or4 in the absence of known or detectable novel pairing/3 
chain (18,  57). 
Recently, Weissman and colleagues have reported that trans- 
fection of c~4 into a/31-expressing melanoma cell results in 
enhanced cell-cell interactions in an assay involving adhesion 
of suspended B16 melanoma cells to an adherent melanoma 
monolayer (58).  Enhanced adhesion was dependent on or4 
expression on both the suspended and monolayer populations, 
leading to the hypothesis that c~4 integrins might in this set- 
ting participate in homotypic molecular interactions.  Our 
study demonstrating that the o~4 integrin chain itself con- 
tains motifs capable of serving as potent or4 integrin binding 
ligands is consistent with this model, and it raises the possi- 
bility that regulated ot4/31 and ol4/37 interaction with cell 
surface or4 represents an important new pathway for the con- 
trol of cell-cell interactions. Formal proof of the involvement 
of or4 as a ligand in particular cell-cell adhesion events must 
await mutagenic analysis, permitting expression of or4 inte- 
grins displaying recognition but not ligand activity, or vice 
versa. 
In summary, this paper characterizes a novel ligand for or4 
integrins, namely the or4 subunit itself. It will be important 
to determine under what physiological conditions or4 is avail- 
able as a ligand for cell-ceU interactions, and whether this 
activity can be regulated coordinately or independently of 
conventional or4 integrin functions. In conjunction with the 
recent evidence that or3 integrins can interact in a homotypic 
fashion (59), our results suggest a novel mechanism by which 
integrins may participate in the complex regulation of cell-cell 
interactions. 
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